Evaluating the Cost-effectiveness of Voclosporin in the United States for the Treatment of Lupus Nephritis (NKF-SCM 2024) - Mar 23, 2024 - Abstract #373; "A phase 3 study found the addition of VCS to mycophenolate mofetil and low-dose glucocorticoids results in clinically significant reductions in proteinuria across racial and ethnic groups. An updated cost-effectiveness analysis found VCS to be substantially below ICER's willingness-to-pay threshold of $150,000 in adult patients with active LN. Moreover, cost-effectiveness was found in a smaller subgroup analysis of Black, Hispanic, and Latino patients, a population disproportionately affected by LN, on par with other interventions for diabetes, blood pressure, and hyperlipidemia. These results are consistent with the original evaluation by ICER demonstrating that VCS continues to be a cost-effective treatment for LN."
Cost effectiveness • HEOR • Diabetes • Diabetic Nephropathy • Dyslipidemia • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology
|
|
Ronald Flauto; Ernie Lee; Victoria Atencio; Vanessa Birardi; Lisa Kennedy
|